

SIgN Immunology Seminar

Dr Kevin Baird

Eijkman-Oxford
Clinical Research Unit
Jakarta, Indonesia



Host: Dr Laurent Renia
Network, A*STAR
Date: Wednesday, 15 February 2012
Time: 3.00pm – 3.30pm
Venue: SIgN Seminar Room, Immunos Building Level 4, Biopolis

Chemotherapeutics Challenges with *Plasmodium vivax*

Plasmodium vivax has been, and continues to be, neglected by policy makers, implementors, and researchers. The growing realization that the parasite causes substantial burdens of morbidity & mortality in endemic zones coincides with the emergence of parasite resistance to the only licensed treatment for acute vivax malaria, chloroquine. The other drug used with chloroquine to prevent relapses, primaquine, may also be compromised by resistance. Facing the threat posed by *P. vivax* requires assessing new companion treatments for radical cure for safety and efficacy in both therapeutic compartments (blood stages & liver stages). This presentation highlights the obstacles to meeting this challenge, and the work necessary to overcome them.